Genentech, Plexxikon win US OK for melanoma Rx, companion Dx
This article was originally published in Scrip
Executive Summary
Treatment for metastatic melanoma took another giant leap forward on 17 August with the US FDA's OK of Genentech's and Plexxikon's BRAF inhibitor Zelboraf (vemurafenib), which was approved alongside a first-of-a-kind companion diagnostic aimed at determining if a patient's melanoma cells have the BRAF V600E mutation.